Sibel Blau

7.5k total citations · 1 hit paper
40 papers, 1.3k citations indexed

About

Sibel Blau is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sibel Blau has authored 40 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Sibel Blau's work include Advanced Breast Cancer Therapies (16 papers), Cancer Treatment and Pharmacology (12 papers) and Cancer Genomics and Diagnostics (7 papers). Sibel Blau is often cited by papers focused on Advanced Breast Cancer Therapies (16 papers), Cancer Treatment and Pharmacology (12 papers) and Cancer Genomics and Diagnostics (7 papers). Sibel Blau collaborates with scholars based in United States, France and Spain. Sibel Blau's co-authors include Petros Nikolinakos, Helmy Eltoukhy, Dave S.�B. Hoon, Stephen G. Divers, AmirAli Talasaz, Richard B. Lanman, Scott Kopetz, Arthur M. Baca, Dragan Sebisanovic and Bahram G. Kermani and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Sibel Blau

37 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

2015 470 citations Richard B. Lanman, Stefanie Mortimer et al. PLoS ONE profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sibel Blau United States	15	735	730	648	310	186	40	1.3k
Konstantinos Tryfonidis Belgium	20	1.1k 1.5×	771 1.1×	406 0.6×	326 1.1×	233 1.3×	53	1.7k
Débora De Melo Gagliato Brazil	14	953 1.3×	501 0.7×	528 0.8×	426 1.4×	144 0.8×	36	1.5k
Editta Baldini Italy	21	1.1k 1.5×	513 0.7×	470 0.7×	319 1.0×	174 0.9×	83	1.5k
Ingvil Mjaaland Norway	20	885 1.2×	822 1.1×	369 0.6×	302 1.0×	135 0.7×	43	1.6k
Kristi McIntyre United States	16	1.6k 2.1×	959 1.3×	405 0.6×	328 1.1×	158 0.8×	39	1.9k
Peter Vuylsteke Belgium	19	1.1k 1.5×	383 0.5×	411 0.6×	439 1.4×	115 0.6×	101	1.7k
Deepa Rangachari United States	22	1.1k 1.5×	430 0.6×	1.3k 2.1×	459 1.5×	124 0.7×	68	1.8k
Bjørnar Gilje Norway	19	578 0.8×	532 0.7×	245 0.4×	302 1.0×	125 0.7×	52	968
Luiz H. Araujo Brazil	13	845 1.1×	391 0.5×	597 0.9×	446 1.4×	107 0.6×	69	1.4k
Tamer M. Fouad United States	19	683 0.9×	425 0.6×	291 0.4×	211 0.7×	106 0.6×	41	1.1k

Countries citing papers authored by Sibel Blau

Since Specialization

Citations

This map shows the geographic impact of Sibel Blau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sibel Blau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sibel Blau more than expected).

Fields of papers citing papers by Sibel Blau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sibel Blau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sibel Blau. The network helps show where Sibel Blau may publish in the future.

Co-authorship network of co-authors of Sibel Blau

This figure shows the co-authorship network connecting the top 25 collaborators of Sibel Blau. A scholar is included among the top collaborators of Sibel Blau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sibel Blau. Sibel Blau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gajra, Ajeet, Sibel Blau, Julio A. Peguero, et al.. (2024). Impact of Exigent Research Network’s partnership with the Tempus AI TIME Program on the screening and matching of patients for clinical trials.. Journal of Clinical Oncology. 42(16_suppl). e13599–e13599. 1 indexed citations

Kolodziej, Michael, et al.. (2024). Symptoms reported by patients using an ePRO compared with those reported to nurses via telephone triage.. Journal of Clinical Oncology. 42(16_suppl). 1542–1542.

Bardia, Aditya, Ciara C. O’Sullivan, Reshma Mahtani, et al.. (2024). An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).. Journal of Clinical Oncology. 42(16_suppl). TPS1122–TPS1122. 1 indexed citations

Damodaran, Senthil, Ciara C. O’Sullivan, Ahmed Elkhanany, et al.. (2023). Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Annals of Oncology. 34(12). 1131–1140. 25 indexed citations

Schmid, Peter, Javier Cortés, Ana Joaquim, et al.. (2023). XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease. Breast Cancer Research. 25(1). 67–67. 12 indexed citations

Seneviratne, Lasika, Kathleen Harnden, Sibel Blau, et al.. (2023). 201P Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Preliminary phase II results. ESMO Open. 8(1). 101390–101390. 5 indexed citations

Dranitsaris, George, Mehdi M. Moezi, Katherine J. Dobson, Robert J. Phelan, & Sibel Blau. (2022). A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Supportive Care in Cancer. 30(8). 6649–6658. 3 indexed citations

Zoň, Robin, Erin B. Kennedy, Kerin B. Adelson, et al.. (2021). Telehealth in Oncology: ASCO Standards and Practice Recommendations. JCO Oncology Practice. 17(9). 546–564. 92 indexed citations

Bardia, Aditya, Sara A. Hurvitz, Angela DeMichele, et al.. (2021). Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clinical Cancer Research. 27(15). 4177–4185. 80 indexed citations

10.

Gajra, Ajeet, et al.. (2021). Augmented Intelligence to Predict 30-day Mortality in Patients with Cancer. Future Oncology. 17(29). 3797–3807. 11 indexed citations

11.

Dent, Rebecca, Mafalda Oliveira, Steven J. Isakoff, et al.. (2020). 139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC). Annals of Oncology. 31. S64–S65. 14 indexed citations

12.

Khan, Qamar J., Anne O’Dea, Aditya Bardia, et al.. (2020). Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).. Journal of Clinical Oncology. 38(15_suppl). 505–505. 47 indexed citations

13.

Soobader, Mah‐Jabeen, et al.. (2018). Reducing Cancer Costs Through Symptom Management and Triage Pathways. Journal of Oncology Practice. 15(2). e91–e97. 14 indexed citations

14.

Gornstein, Erica, Jon Chung, Laurie M. Gay, et al.. (2017). BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. Clinical Breast Cancer. 18(2). 184–188. 36 indexed citations

15.

Szeto, Christopher W., Stephen C. Benz, Franco Cecchi, et al.. (2017). Investigating tumoral and temporal heterogeneity through comprehensive -omics profiling in patients with metastatic triple negative breast cancer.. Journal of Clinical Oncology. 35(15_suppl). 1093–1093. 2 indexed citations

16.

Lyman, Gary H., Catherine R. Fedorenko, Laura Panattoni, et al.. (2017). Patterns in provider types and cost of surveillance testing in early-stage breast cancer patients: A regional study.. Journal of Clinical Oncology. 35(15_suppl). 6582–6582. 1 indexed citations

17.

Kuderer, Nicole M., Kimberly A. Burton, Sibel Blau, et al.. (2016). Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology. JAMA Oncology. 3(7). 996–996. 109 indexed citations

18.

Lanman, Richard B., Stefanie Mortimer, Oliver A. Zill, et al.. (2015). Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS ONE. 10(10). e0140712–e0140712. 470 indexed citations breakdown →

19.

Campton, Daniel, Arturo B. Ramirez, Joshua J. Nordberg, et al.. (2015). High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer. 15(1). 360–360. 129 indexed citations

20.

Overton, Lindsay, Christopher L. Corless, Manish Agrawal, et al.. (2014). Impact of next-generation sequencing (NGS) on treatment decisions in the community oncology setting.. Journal of Clinical Oncology. 32(15_suppl). 11028–11028. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact